ECM
RCUS icon

Endurant Capital Management’s Arcus Biosciences RCUS Stock Holding History

Endurant Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-97,327
Closed -$2.55M – 69
2022
Q3 		$2.55M Buy
97,327
+32,571
+50% +$861K 0.83% 29
2022
Q2 		$1.64M Buy
64,756
+26,106
+68% +$639K 0.58% 37
2022
Q1 		$1.22M Buy
+38,650
New +$1.3M 0.32% 49

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Endurant Capital Management's RCUS Position: Q4 2022 in Review

Endurant Capital Management sold out of Arcus Biosciences (RCUS) in Q4 2022, closing a stake of 97,327 shares — an estimated $2.55M sold.

Endurant Capital Management first reported a position in RCUS in Q1 2022 and held it in 3 quarters. The position peaked at $2.55M in Q3 2022. 200 funds tracked by Wall St. Rank hold RCUS as of Q4 2022.

  • Endurant Capital Management reported no remaining Arcus Biosciences position as of Q4 2022 after selling out during the quarter.
  • Endurant Capital Management sold 97,327 Arcus Biosciences shares in Q4 2022, an estimated $2.55M.
  • Endurant Capital Management first reported a position in Arcus Biosciences in Q1 2022 and held it in 3 quarters.
  • Endurant Capital Management's Arcus Biosciences position peaked at $2.55M in Q3 2022.
  • 200 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2022.

Based on Endurant Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.